Fortum powder for solution for injections/infusions 1g. №1


Manufacturer: Italy

endoscopic or radiological examination of the large intestine; surgery on the large intestine.



Fortum for injections/infusions Storage
active substance: ceftazidime;

1 vial contains ceftazidime (in the form of ceftazidime pentahydrate) 500 mg or 1 g or 2 g;

Excipient: sodium carbonate anhydrous.

Fortum for injections/infusions Dosage form
Powder for solution for injection.

Basic physical and chemical properties: from white to cream color powder.

Fortum for injections/infusions Pharmacotherapeutic group
Antibacterial agent for systemic use. Cephalosporins of the third generation. ATX code J01D D02.

Pharmacological properties


Ceftazidime is a bactericidal cephalosporin antibiotic whose mechanism of action is associated with impaired bacterial cell wall synthesis.

Acquired antibiotic resistance varies from region to region and may change over time, and may differ significantly for individual strains. It is desirable to use local data on antibiotic susceptibility and data on the spread of microorganisms that produce beta-lactamases with an extended spectrum of action, especially in the treatment of severe infections.

Sensitive microorganisms

Gram-positive aerobes: Streptococcus pyogenes, Streptococcus agalactiae.

Gram-negative aerobes: Citrobacter koseri, Haemophilus influenzae, Moraxella catarrhalis, Neisseria meningitides, Proteus mirabilis, Proteus spp., Providencia spp., Pasteurella multocida

Strains with possible acquired resistance

Gram-negative aerobes: Acinetobacter baumannii, Burkholderia cepacia, Citrobacter freundii, Enterobacter aerogenes, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Klebsiella spp., Pseudomonas aeruginosa, Serratia slaganii, Morga.

Treatment of the following infections in adults and children, including newborns:

nosocomial pneumonia;
respiratory tract infections in patients with cystic fibrosis;
bacterial meningitis;
chronic otitis media;
malignant otitis externa;
complicated urinary tract infections;
complicated skin and soft tissue infections;
complicated infections of the abdominal cavity;
bone and joint infections;
peritonitis associated with dialysis in patients on continuous ambulatory peritoneal dialysis.
Treatment of bacteremia that occurs in patients as a result of any of the above infections.

Ceftazidime can be used to treat patients with neutropenia and fever caused by a bacterial infection.

Ceftazidime can be used to prevent urinary tract infections during prostate surgery (transurethral resection).

When prescribing ceftazidime should take into account its antibacterial spectrum, directed mainly against gram-negative aerobes (see sections “Peculiarities” and “Pharmacological properties”).

Ceftazidime should be used with other antibacterial agents if a number of the microorganisms that caused the infection are not expected to fall within the spectrum of action of ceftazidime.

The drug should be prescribed in accordance with the existing official recommendations for the appointment of antibacterial agents.

Hypersensitivity to ceftazidime or to other components of the drug.
Hypersensitivity to cephalosporin antibiotics.
Presence of a history of severe hypersensitivity (eg, anaphylactic reactions) to other beta-lactam antibiotics (penicillins, monobactams and carbapenems).